Search Results
Your search for ASCO matches 408 pages
Showing 351 - 400FDA Approves New Indication for Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
The U.S. Food and Drug Administration (FDA) has approved a new indication for the use of enzalutamide (Xtandi) capsules to treat patients with metastatic castration-resistant prostate cancer. The new indication is for men with metastatic castration-resistant prostate cancer who have not received...
ASCO and Cancer Care Ontario Release Clinical Practice Guideline for Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer
The ASCO Clinical Practice Guidelines Committee and the Cancer Care Ontario (CCO) program in evidence-based care have released a clinical practice guideline on systemic therapy in men with metastatic castration-resistant prostate cancer. The guideline is reported by Basch et al in the Journal of...
RNA Sequencing Could Help Doctors Tailor Unique Prostate Cancer Treatment Programs
Sequencing RNA, not just DNA, could help doctors predict how prostate cancer tumors will respond to treatment, according to research published in the journal Genome Biology. Because a tumor’s RNA shows the real-time changes a treatment is causing, the authors believe that this could be a...
Study Finds Widespread Adoption of Robot-Assisted Prostatectomy in United States
A new study reveals that the United States has experienced widespread adoption of robot-assisted prostatectomy to treat prostate cancer in recent years. The findings, reported by Chang et al in BJU International, also showed that although such surgeries are more expensive than traditional...
Swedish Study Reports Increasing Rates of Severe Infection Requiring Hospitalization After Prostate Biopsy
Transrectal ultrasound guided biopsy is the standard for detecting prostate cancer, but international reports have suggested that the risks associated with the procedure are increasing. In a new nationwide population-based study reported in The Journal of Urology, Swedish researchers found that 6%...
Prostate Cancer Prevention Trial Identifies Men Most Likely to Undergo Challenging Study Procedures
Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all steps of the clinical trial are most likely to undergo a biopsy, according to a study by Gritz et al published in Cancer Epidemiology, Biomarkers & Prevention. The Prostate Cancer Prevention Trial, ...
College of American Pathologists Publishes Recommendations for Prostate Cancer Active Surveillance
Prostate cancer is the second leading cause of cancer death in men in the United States. Active surveillance offers low-risk prostate cancer patients a means to avoid the potentially harmful side effects from treatment. In a recent article in the Archives of Pathology & Laboratory Medicine, a...
Robot-Assisted Surgery for Localized Prostate Cancer Controls Disease for 10 Years
Robot-assisted surgery to remove cancerous prostate glands is effective in controlling the disease for 10 years, according to a new study led by researchers at Henry Ford Hospital. The study by Diaz et al, published in European Urology, also suggested that traditional methods of measuring the...
Variations in Key Gene Predict Prostate Cancer Patients’ Risk for Radiation-Induced Toxicity
Key genetic variants may affect how cancer patients respond to radiation treatments, according to a study recently published in Nature Genetics. The research team, which included researchers at the Icahn School of Medicine at Mount Sinai, found that variations in the TANC1 gene are associated with...
Development of Orteronel for Prostate Cancer Voluntarily Discontinued by Takeda
Takeda Pharmaceutical Company Limited announced today that it has voluntarily decided to end the development program for orteronel (TAK-700), an investigational oral, nonsteroidal, selective inhibitor of 17,20-lyase, for prostate cancer. The decision follows the results of two phase III...
ASCO 2014: Enzalutamide Before Chemotherapy Prolongs Progression-Free and Overall Survival in Metastatic Prostate Cancer
The androgen receptor inhibitor enzalutamide (Xtandi) has been shown to prolong survival in men with metastatic castration-resistant prostate cancer with progressive disease after chemotherapy. In the phase III PREVAIL trial reported in The New England Journal of Medicine, Beer et al found that...
ASCO 2014: Adding Docetaxel to Androgen-Deprivation Therapy Significantly Improves Survival in Hormone-Sensitive Prostate Cancer
The addition of docetaxel to androgen-deprivation therapy extended survival for men with newly diagnosed hormone-sensitive prostate cancer by more than 13 months in the National Cancer Institute–led phase III E3805 study. The survival benefit was even greater for men with high-volume disease. ...
ASCO 2014: Men Who Receive Radiation Therapy for Prostate Cancer Have Increased Long-Term Risk of Bladder or Rectal Cancer
Men with prostate cancer generally have an excellent prognosis, but questions remain about the risk of second primary malignancies after initial therapy for localized disease. According to a new study presented at the 2014 ASCO Annual Meeting in Chicago (Abstract 5034), although the overall risk of ...
Study Reveals More Than One-Third of Patients With ‘Low-Risk’ Prostate Cancer on Conventional Biopsy Have More Aggressive Tumors on Targeted Biopsy
According to a new study by researchers at the University of California, Los Angeles, selection of men for active surveillance for prostate cancer should be based not on conventional biopsy, but on a new, imaging-guided targeted prostate biopsy. The new biopsy method is now a routine part of the...
Results of Three Studies Indicate 17-Gene Assay Is a Significant Predictor of Prostate Cancer Aggressiveness at the Time of Diagnosis
According to the results from three studies published in European Urology, the 17-gene Oncotype DX Genomic Prostate Score is a significant predictor of disease aggressiveness at the time of diagnosis before intervention with radiation or surgery. The test provides more precise and individualized...
Delaying Androgen Deprivation Therapy May Be Safe for Men With Prostate Cancer Relapse Detected by PSA Testing
According to a large, population-based observational study of men who had a prostate-specific antigen (PSA)-only based relapse after prostate surgery or radiation therapy, delaying androgen deprivation therapy until the onset of symptoms or appearance of cancer on a scan does not substantially...
Statin Use Associated With Reduced Risk of Prostate Cancer Recurrence
Men who begin taking statins after prostate cancer surgery are less likely to have a recurrence of their cancer, according to a retrospective analysis led by researchers at Duke Medicine. The study by Allott et al was published in BJU International. “Our findings suggest that beginning...
Experimental Drug Receives Fast Track Designation as Second-Line Chemotherapy for Metastatic Castration-Resistant Prostate Cancer
OncoGenex Pharmaceuticals, Inc, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of custirsen (OGX-011) when administered in combination with cabazitaxel (Jevtana Kit)/prednisone for the treatment of men with metastatic...
Study Finds a Quarter of Men Drop Out of Prostate Cancer Monitoring, Casting Doubt on Safety of Active Surveillance
Noncompliance appears to be a major challenge for active surveillance, according to the results of long-term follow-up of patients with prostate cancer presented at the European Association of Urology 29th Annual Congress in Stockholm. Over a quarter of men dropped out of the active surveillance...
Six Months Hormonal Treatment in Addition to Radiotherapy Improves Survival for Men With Localized Prostate Cancer
Men with localized prostate cancer that is at risk of growing and spreading have a lower risk of disease progression and recurrence if they are treated with radiotherapy combined with androgen-deprivation therapy, according to new research. The findings, which were presented at the 33rd Conference...
New Test Developed to Detect Men at High Risk of Prostate Cancer Recurrence
A new genetic signature to identify prostate cancer patients who are at high risk of their cancer recurring after surgery or radiotherapy has been developed by researchers in Canada, according to a study presented at the 33rd Conference of the European Society for Radiotherapy and Oncology in...
Dose-Escalated Hypofractionated IMRT for Localized Prostate Cancer Has Similar Side Effects Compared to Conventional IMRT
Dose-escalated intensity-modulated radiotherapy with use of a moderate hypofractionation regimen (72 Gy in 2.4-Gy fractions) can safely treat patients with localized prostate cancer with limited grade 2 or 3 late toxicity, according to a study by Hoffman et al published in the International Journal ...
BPA Exposure May Be Linked to Prostate Cancer, Study Shows
A new study suggests that levels of bisphenola A (BPA) in men’s urine may be a marker of prostate cancer and that low levels of BPA exposure can cause cellular changes in both nonmalignant and malignant prostate cells. The research, published in PLOS ONE, provides the first evidence that...
Robotic-Assisted Prostate Surgery May Offer Better Cancer Control Than Open Radical Prostatectomy
An observational study from UCLA’s Jonsson Comprehensive Cancer Center comparing robotic-assisted surgery to traditional surgery for prostate cancer found that patients who had robotic surgery had fewer instances of cancer cells remaining after surgery and less need of additional cancer...
Selenium and Vitamin E Supplements May Increase Risk of Prostate Cancer in Some Men
A multicenter study led by Fred Hutchinson Cancer Research Center has found that high-dose supplementation with both the trace element selenium and vitamin E may increase the risk of high-grade prostate cancer. This risk is dependent upon a man’s selenium status prior to taking the...
Tasquinimod May Improve Survival in Men With Metastatic Prostate Cancer
An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute. The study, published in the journal Clinical Cancer Research, adds...
Shortened Telomeres in Blood Leukocytes May Be Associated With Increased Risk of Aggressive Prostate Cancer
Men with short-ended chromosomes in the immune cells in their blood were at increased risk for aggressive prostate cancer compared with men with long-ended chromosomes in blood immune cells, according to results presented at the 12th Annual AACR International Conference on Frontiers in Cancer...
Men With Advanced Prostate Cancer Worry More About Burdening Family and Friends Than Dying, Survey Finds
Men with advanced prostate cancer are now living longer than ever, and it is estimated that one in six U.S. men will be diagnosed with prostate cancer in their lifetime. However, little research has been conducted to understand the psychosocial needs of these men and their caregivers after...
Telomere Length May Be a Prognostic Marker for Prostate Cancer
Cancer cells are known to have short telomeres, but just how short they are from cancer cell to cancer cell may be a determining factor in a prostate cancer patient's prognosis, according to a study led by scientists at Johns Hopkins. "Doctors are looking for new ways to accurately predict...
Abiraterone Acetate/Prednisone Combination Delays Decline in Quality of Life in Men With Metastatic Prostate Cancer
According to a study published in The Lancet Oncology, abiraterone acetate (Zytiga) taken in conjunction with prednisone significantly delays progression of pain and quality of life deterioration in men with metastatic castration-resistant prostate cancer. The study was led by Ethan Basch, MD,...
ASTRO: Fewer Weeks of Neoadjuvant Hormone Therapy Reduces Side Effects in Patients With Intermediate-Risk Prostate Cancer
A shorter course of androgen suppression therapy prior to radiation therapy, when compared to an extended course of androgen suppression therapy, yields comparable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented today at the...
ASTRO: Long-Term Androgen Deprivation in Patients With Intermediate-Risk Prostate Cancer Does Not Improve Overall Survival
A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy. Investigators concluded that there were no additional benefits when compared to short-term...
Test Could Identify Which Prostate Cancers Require Treatment
The level of expression of three genes associated with aging can be used to predict whether seemingly low-risk prostate cancer will remain slow-growing, according to researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center (CUMC). Use of this three-gene...
Germline Missense Mutations in BTNL2 Increase Susceptibility to Prostate Cancer
A team of researchers led by Janet Stanford, PhD, of Fred Hutchinson Cancer Research Center has discovered that mutations in the gene BTNL2, which encodes a protein involved in regulating T-cell proliferation and cytokine production—both of which impact immune function—increase the risk ...
Researchers Identify Key Protein in Treatment-Resistant Prostate Cancer
Prostate cancer is one of the most common forms of cancer in men and the leading cause of cancer deaths in white, African American, and Hispanic men, according to the Centers for Disease Control. However, it remains unclear why, despite treatment, some prostate cancers progress and may become...
Researchers Identify Key Mechanism Behind Castration-Resistant Prostate Cancer
A team of researchers from UC Davis, UC San Diego, and other institutions has identified a key mechanism behind aggressive prostate cancer. Published online today in Nature, the study shows that two long noncoding RNAs, PRNCR1 and PCGEM1, activate androgen receptors, circumventing...
Researchers Uncover How a Potent Compound Kills Prostate Cancer Cells
A new study led by researchers at Sanford-Burnham Medical Research Institute reveals how a promising anticancer compound called SMIP004 specifically kills prostate cancer cells by compromising their ability to withstand environmental stress. The study, recently published in Oncotarget, uncovered...
Decision Aids Reduce Men's Conflict about PSA Screening, but Don't Change Their Decisions
Men who decide to be screened for prostate cancer and those who forgo PSA screening stick with their decisions after receiving materials explaining the risks and benefits of the test, according to a study published in JAMA Internal Medicine. The study examined both Web-based and printed tools aimed ...
Use of Androgen Deprivation Therapy for Treatment of Prostate Cancer Associated with Increased Risk of Acute Kidney Injury
In a study that included more than 10,000 men with nonmetastatic prostate cancer, use of androgen deprivation therapy was associated with a significantly increased risk of acute kidney injury, with variations observed with certain types of androgen deprivation therapies, according to a study in the ...
Nerves Play Key Role in Triggering Prostate Cancer and Promoting Metastases
Researchers at Albert Einstein College of Medicine of Yeshiva University have found that nerves play a critical role in both the development and spread of prostate tumors. Their findings, using both a mouse model and human prostate tissue, may lead to new ways to predict the aggressiveness of...
Study Confirms Link Between High Blood Levels of Omega-3 Fatty Acids and Increased Risk of Aggressive Prostate Cancer
A second large, prospective study by scientists at Fred Hutchinson Cancer Research Center has confirmed the link between high blood concentrations of omega-3 fatty acids and an increased risk of prostate cancer. Study Details Published online in the Journal of the National Cancer Institute, the...
Soy Protein Supplementation Does Not Reduce Risk of Prostate Cancer Recurrence after Radical Prostatectomy
Among men who had undergone radical prostatectomy, daily consumption of a beverage powder supplement containing soy protein isolate for 2 years did not reduce or delay development of biochemical recurrence of prostate cancer compared to men who received placebo, according to a study in the July 10...
Active Surveillance May Miss Aggressive Prostate Cancers in African American Men
A study of more than 1,800 men aged 52 to 62 suggests that African Americans diagnosed with very low-risk prostate cancers are much more likely than white men to actually have aggressive disease that goes unrecognized with current diagnostic approaches. Although prior studies have found it safe to...
Use of Advanced Treatment Technologies Increases among Men at Low Risk of Dying from Prostate Cancer
Use of advanced treatment technologies for prostate cancer, such as intensity-modulated radiotherapy (IMRT) and robotic prostatectomy, has increased among men with low-risk disease, high risk of noncancer mortality, or both, a population of patients who are unlikely to benefit from these...
Observation Is Safe, Cost-saving Option for Patients with Low-risk Prostate Cancer
Many men with low-risk, localized prostate cancers can safely choose active surveillance or watchful waiting instead of undergoing immediate treatment and have better quality of life while reducing health-care costs, according to a study by researchers at Dana-Farber Cancer Institute and...
New Possibilities for Prostate Cancer Treatment
An Australian study has identified a subgroup of prostate cancer cells that survive androgen deprivation therapy and could contribute to prostate cancer recurrence. Previously unidentified, these cells are potential targets for future treatments. As they are present early in disease development,...
Researchers Identify Novel Class of Drugs for Prostate Cancers
A new study on prostate cancer describes a novel class of drugs developed by UT Southwestern Medical Center researchers that interrupts critical signaling needed for prostate cancer cells to grow. In men with advanced prostate cancer, growth of cancer cells depends on androgen receptor signaling,...
Mayo Clinic Genomic Analysis Lends Insight to Prostate Cancer
Mayo Clinic researchers have used next-generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings appear online today in the journal Cancer Research. Gleason Patterns...
Phase II Trial Targeting Genetic Anomaly in Castration-resistant Metastatic Prostate Cancer Underway
A new clinical trial is testing whether targeting treatments to a genetic anomaly can lead to better treatments for castration-resistant metastatic prostate cancer. The trial, led by investigators at the University of Michigan Comprehensive Cancer Center, is being conducted at 11 sites throughout...
ASCO 2013: PARP Inhibitor Shows Activity in Pancreatic, Prostate Cancers among Patients Carrying BRCA Mutations
In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study, led by researchers ...
